Eisai Expands Direct Presence in Saudi Arabia with New Pharmaceutical Sales Subsidiary

02 October 2024 | Wednesday | News


Eisai Saudi Arabia begins full-scale operations, marking the company's shift to in-house sales and marketing for key treatments like Methycobal® and Fycompa®, with plans to expand its portfolio and strengthen its presence in the region's largest pharmaceutical market.
Image Source : Public Domain

Image Source : Public Domain

Eisai announced the commencement of full-scale operations at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a wholly-owned subsidiary established in Riyadh. This new pharmaceutical sales entity, under the umbrella of Eisai Europe Ltd., marks Eisai's direct entry into the Saudi market after decades of working through local distribution partners.

Eisai’s presence in the Middle East dates back to the 1960s, and in 2009, the company launched its peripheral neuropathy treatment Methycobal® in Saudi Arabia. Since then, it has introduced a range of treatments, including the antiepileptic drug Fycompa® (2018) and the anticancer drug Lenvima® (2020). The establishment of Eisai Saudi Arabia in April 2024 reflects the company's strategic shift to in-house sales and marketing operations, taking over commercial rights from local partners.

October 2024 marks the start of sales activities for Methycobal and Fycompa under the new structure, with plans to expand operations to include Lenvima and the anticancer drug Halaven® in April 2025. In addition, Eisai has submitted an application for the approval of lecanemab (global brand name: Leqembi®), an Alzheimer’s disease treatment, which is currently under review in Saudi Arabia.

Saudi Arabia's pharmaceutical market, valued at USD 11.34 billion in 2023, is the largest in the Middle East and has seen an average growth rate of 7% from 2019 to 2023. With the launch of Eisai Saudi Arabia, Eisai aims to strengthen its presence in this vital market, providing innovative treatments to more patients in the region and improving patient outcomes and care.

Outline of Eisai Saudi Arabia:

  1. Company Name: Eisai Pharmaceuticals Single Person Limited Liability Company
  2. Location: Riyadh, Kingdom of Saudi Arabia
  3. Scope of Business: Import and marketing of pharmaceutical products
  4. Charter Capital: 32,800,000 Saudi Riyal (approximately 1.25 billion JPY)
  5. Shareholder: Eisai Europe Ltd.
  6. Date of Establishment: April 2, 2024

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close